Theory and practice of supersaturatable formulations for poorly soluble drugs

Therapeutic Delivery

Volumn 6, Issue 3, 2015, Pages 339-352

  Kawakami, Kohsaku ^a  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; NANOCRYSTAL; EMULSION; NANOPARTICLE;

DISPERSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG STABILITY; INDUSTRIAL PRODUCTION; MISCIBILITY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; EMULSION; MEDICINAL CHEMISTRY; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; NANOPARTICLES; SOLUBILITY;

EID: 84927664585     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.116     Document Type: Review

References (65)

1. Kawakami K. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv. Drug Deliv. Rev. 64(6), 480-495 (2012).
2. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21(2), 201-230 (2004).
3. Kawakami K, Miyoshi K, Ida Y. Solubilization behavior of poorly soluble drugs with combined use of gelucire 44/14 and cosolvent. J. Pharm. Sci. 93(6), 1471-1479 (2004).
4. Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 28(1-2), 7-14 (2006).
5. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 52(8), 900-915 (2004).
6. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59(7), 645-666 (2007).
7. Yang G, Jain N, Yalkowsky SH. Combined effect of SLS and (SBE)7M-beta-CD on the solubilization of NSC-639829. Int. J. Pharm. 269(1), 141-148 (2004).
8. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. Thermodynamic analysis. J. Pharm. Sci. 99(3), 1254-1264 (2010).
9. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98(8), 2549-2572 (2009).
10. Verreck G, Vandecruys R, De Conde V et al. The use of three different solid dispersion formulations - melt extrusion, filmcoated beads, and a glass thermoplastic system - to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J. Pharm. Sci. 93(5), 1217-1228 (2004).
11. Zhang S, Kawakami K, Yamamoto M et al. Coaxial electrospray formulations for improving oral absorption of a poorly water-soluble drug. Mol. Pharm. 8(3), 807-813 (2011).
12. Mah PT, Laaksonen, T, Rades T et al. Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide. Mol. Pharm. 11(1), 234-242 (2014).
13. Alonzo DE, Gao Y, Zhou D et al. Dissolution and precipitation behavior of amorphous solid dispersions. J. Pharm. Sci. 100(8), 3316-3331 (2011).
14. Higashi K, Yamamoto K, Pandey MK et al. Insights into atomic-level interaction between mefenamic acid and Eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy. Mol. Pharm. 11(1), 351-357 (2014).
15. Pongpeerapat A, Wanawongthai C, Tozuka Y, Moribe K, Yamamoto K. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int. J. Pharm. 352(1-2), 309-316 (2008).
16. Ueda K, Higashi K, Yamamoto K, Moribe K. The effect of HPMCAS functional groups on drug crystallization from the supersaturated state and dissolution improvement. Int. J. Pharm. 464(1-2), 205-213 (2014).
17. Yin L, Hillmyer MA. Preparation and performance of hydroxypropyl methylcellulose esters of substituted succinates for in vitro supersaturation of a crystalline hydrophobic drug. Mol. Pharm. 11(1), 175-185 (2014).
18. Kawakami K, Harada T, Miura K et al. Relationship between crystallization tendencies during cooling from melt and isothermal storage: toward a general understanding of physical stability of pharmaceutical glasses. Mol. Pharm. 11(6), 1835-1843 (2014).
19. Kawakami K. Surface effects on the crystallization of ritonavir glass. J. Pharm. Sci. 104(1), 276-279 (2015).
20. Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage - impact of different polymers. J. Pharm. Sci. 102(1) 171-184 (2013).
21. Janssens S, De Zeure A, Paudel A et al. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and Eudragit E100. Pharm. Res. 27(5), 775-785 (2010).
22. Guns S, Dereymaker A, Kayaert P et al. Comparison between hot-melt extrusion and spray-drying for manufacturing solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm. Res. 28(3), 673-682 (2011).
23. Bank M, Leffingwell J, Thies C. The influence of solvent upon the compatibility of polystyrene and poly(vinyl methyl ether). Macromolecules 4(1), 43-46 (1971).
24. Kawakami K, Hasegawa Y, Deguchi K et al. Competition of thermodynamic and dynamic factors during formation of multi-component particles via spray-drying. J. Pharm. Sci. 102(2), 518-529 (2013).
25. Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with Neusilin. J. Pharm. Sci. 92(3), 536-551 (2003).
26. Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. Int. J. Pharm. 453(1), 181-197 (2013).
27. Crowley KJ, Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm. Sci. 91(2), 492-507 (2002).
28. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88(10), 1058-1066 (1999).
29. Sollohub K, Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J. Pharm. Sci. 99(2), 587-597 (2010).
30. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54(2), 107-117 (2002).
31. Repka MA, Shah S, Lu J et al. Melt extrusion: process to product. Exp. Opin. Drug Deliv. 9(1), 105-125 (2012).
32. Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur. J. Pharm. Sci. 15(2), 115-133 (2002).
33. Yasuji T, Takeuchi H, Kawashima Y. Particle design of poorly water-soluble substances using supercritical fluid technologies. Adv. Drug Deliv. Rev. 60(3), 388-398 (2008).
34. Rumondor ACF, Marsac RJ, Stanford LA, Taylor LS. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol. Pharm. 6(5), 1492-1505 (2009).
35. Marsac RJ, Rumondor ACF, Nivens DE et al. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J. Pharm. Sci. 99(1), 169-185 (2010).
36. Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res. 11(4), 471-477 (1994).
37. Dong Z, Chatterji A, Sandhu H et al. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int. J. Pharm. 355(1-2), 141-149 (2008).
38. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 9(11), 866-872 (1961).
39. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18(2), 113-120 (2003).
40. Van Eedenbrugh B, Van den Mooter G, Augustijins P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364(1), 64-75 (2008).
41. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59(7), 631-644 (2007).
42. Heng JYY, Thielmann F, Williams DR. The effects of milling on the surface properties of form I paracetamol crystals. Pharm. Res. 23(8), 1918-1927 (2006).
43. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13(12), 1838-1845 (1996).
44. Lai SK, O'Hanlon DE, Harrold S et al. Rapid Transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 104(5), 1482-1487 (2007).
45. Wanawongthai C, Pongpeerapat A, Higashi K et al. 2009. Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground mixture. Int. J. Pharm. 376(1-2), 169-175 (2009).
46. Rasenack N, Hartenhauer H, Müller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 254(2), 137-145 (2003).
47. De Waard H, Hinrichs WLJ, Frijlink HW. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J. Control. Release 128(2), 179-183 (2008).
48. Lee J, Choi, JY, Park CH. Characteristics of polymers enabling nano-comminution of water-insoluble drugs. Int. J. Pharm. 355(1-2), 328-336 (2008).
49. George M, Ghosh I. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. Eur. J. Pharm. Sci. 48(1-2), 142-152 (2013).
50. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freezedrying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 58(15), 1688-1713 (2006).
51. Kawakami K, Nishihara Y, Hirano K. Effect of hydrophilic polymers on physical stability of liposome dispersions. J. Phys. Chem. B 105(12), 2374-2385 (2001).
52. Wu Y, Loper A, Landis E et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285(1-2), 135-146 (2004).
53. Brough C, Williams III, RO. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int. J. Pharm. 453(1), 157-166 (2013).
54. Li W, Quan P, Zhang Y et al. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions. Int. J. Pharm. 460(1-2), 13-23 (2014).
55. Kawakami K, Yoshikawa T, Moroto Y et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. J. Control. Release 81(1-2), 65-74 (2002).
56. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45(1-2), 89-121 (2000).
57. Rane SS, Anderson BD. What determines drug solubility in lipid vehicles: is it predictable? Adv. Drug Deliv. Rev. 60(6), 638-656 (2008).
58. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83(3), 444-446 (1994).
59. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 60(6), 673-691 (2008).
60. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 21(8), 1405-1412 (2004).
61. Cuine JF, McEvoy CL, Charman WN et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci. 97(2), 995-1012 (2008).
62. Kawakami K, Yoshikawa T, Hayashi T, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J. Control. Release 81(1-2), 75-82 (2002).
63. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 21(2), 261-270 (2004).
64. Gao P, Rush BD, Pfund WP et al. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92(12), 2386-2398 (2003).
65. Kawakami K. Current status of amorphous formulation and other supersaturatable dosage forms as formulations for early clinical phases. J. Pharm. Sci. 98(9), 2875-2885 (2009).